Methods for treatment with bucindolol based on genetic targeting
View Patent ↗The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor (AR).
1. A method for treating a human patient for heart failure, cardiac arrhythmia, or hypertension with bucindolol comprising: administering bucindolol to the patient if the patient is determined to be homozygous for Arg389 in the β 1 andrenergic receptor (AR) gene based on a test of a biological sample from the patient.
2. The method of claim 1 , wherein the results are obtained by receiving a report containing the information or taking a patient history that reveals the results.
3. The method of claim 1 , wherein bucindolol is formulated for oral administration.
4. The method of claim 1 , wherein the patient is also treated with ACE inhibitors, digoxin or a diuretic.
5. The method of claim 1 , wherein bucindolol is administered every 12 hours.
6. The method of claim 1 , further comprising ordering a test from a sample from the patient that determines the patient's genotype.
7. A method for administering bucindolol to a human patient with symptoms of or a diagnosis of heart failure, cardiac arrhythmia, or hypertension comprising: administering bucindolol to the patient after bucindolol is prescribed for the patient based on test results indicating that the patient's genotype is homozygous for Arg389 in the β 1 adrenergic receptor (AR) gene.
8. The method of claim 7 , wherein the results are obtained by receiving a report containing the information or taking a patient history that reveals the results.
9. The method of claim 7 , wherein bucindolol is formulated for oral administration.
10. The method of claim 7 , wherein the patient is also treated with ACE inhibitors, digoxin or a diuretic.
11. The method of claim 7 , wherein bucindolol is administered every 12 hours.
12. The method of claim 7 , wherein the information is obtained by ordering a test from a sample from the patient that determines the patient's genotype.
13. A method for treating a human patient for heart failure, cardiac arrhythmia, or hypertension with bucindolol comprising:
a) obtaining results from a test that determines whether the patient's genotype is homozygous for Arg389 in the β 1 adrenergic receptor (AR) gene; and,
b) then treating the patient with bucindolol if the test indicates that the patient's genotype is homozygous for Arg389 in the β 1 AR gene.
14. The method of claim 13 , wherein the results are obtained by receiving a report containing the information or taking a patient history that reveals the results.
15. The method of claim 13 , wherein bucindolol is formulated for oral administration.
16. The method of claim 13 , wherein the patient is also treated with ACE inhibitors, digoxin or a diuretic.
17. The method of claim 13 , further comprising ordering a test from a sample from the patient that determines the patient's genotype.
18. A method for treating heart failure or cardiac arrhythmia comprising administering bucindolol to a heart failure or cardiac arrhythmia human patient who has been determined to be homozygous for Arg389 in the β 1 andrenergic receptor (AR) gene based on a test of a biological sample from the patient.
19. The method of claim 18 , wherein bucindolol is formulated for oral administration.
20. The method of claim 18 , wherein the patient is also treated with ACE inhibitors, digoxin or a diuretic.
21. The method of claim 18 , wherein bucindolol is administered every 12 hours.
22. The method of claim 18 , further comprising ordering a test using a sample from the patient that determines the patient's genotype.